KPMG
12.5.2021 03:51:10 CEST | Business Wire | Press release
Ogletree Deakins and KPMG Law in Germany1 are forming a global alliance to provide businesses with global workforce solutions. This alliance will be instrumental in expanding immigration and employment law reach for both organizations and will enable KPMG firms outside of the US2 to bring the US capability and services of Ogletree Deakins to their clients around the world.
The alliance is in response to growing client demand for a technology-powered, globally unified approach to business challenges faced in the areas of immigration and global mobility, labor and employment, and the associated tax, compensation, and benefits issues. This non-exclusive alliance with Ogletree Deakins does not include KPMG in the US or entities that it owns or controls, which do not provide legal services3 .
“As businesses expand and look to shore up recovery in the post-pandemic world, there is increasing pressure for multinational organizations seeking to get the right people in the right places at the right time, and in compliance with the requirements of any given jurisdiction,” said Thomas Wolf , Head of Global Immigration Services for the KPMG organization. “Ogletree Deakins’ labor, employment and immigration experience in the United States is a perfect fit for KPMG’s organization of firms as we expand our global legal services practice4 and our global mobility services offerings around the world. We are excited to join forces with Ogletree Deakins to offer clients even deeper global coverage for their pressing employment and immigration legal matters.”
Both Ogletree Deakins and KPMG Law in Germany are leaders in utilizing technology and innovation to enhance client service, including in the areas of artificial intelligence, data analytics and knowledge management. By combining the strengths of both organizations, this new alliance will provide clients with an increased breadth of technology solutions. KPMG Law in Germany is part of the broader KPMG Law / Global Legal Services network across KPMG firms, with 2,800 lawyers in 81 jurisdictions.
“Ogletree Deakins is an international labor and employment firm and has established an extensive network of lawyers practicing in 53 offices across North America and in Europe to meet our clients’ needs. Our alliance with KPMG Law in Germany will benefit clients by complementing our US labor, employment and immigration offerings with ‘end-to-end’ workplace solutions—including tax, compensation, global immigration, and related advisory and consulting services, over a truly global footprint. Our firm shares a vision with the KPMG network for client service, innovation and cutting-edge technology solutions, and we are already working together on a next generation mobility services platform,” said Matt Keen , managing shareholder of Ogletree Deakins.
About Ogletree Deakins
Ogletree Deakins is one of the largest US labor and employment law firms representing management in all types of employment-related legal matters. Premier client service, as outlined in the firm’s Client Pledge, is one of the firm’s top priorities and a cornerstone of its core values. U.S. News – Best Lawyers® “Best Law Firms” has named Ogletree Deakins a “Law Firm of the Year” for 10 consecutive years. In 2021, the publication named Ogletree Deakins its “Law Firm of the Year” in the Litigation – Labor & Employment category. Ogletree Deakins has more than 900 attorneys located in 53 offices across the United States and in Europe, Canada, and Mexico. The firm represents a diverse range of clients, from small businesses to Fortune 50 companies. More: ogletree.com.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: kpmg.com
_______________________________
1 The agreement will be initially signed by KPMG Law Rechtsanwaltsgesellschaft mbH (“KPMG Law in Germany”), which is associated with KPMG AG Wirtschaftsprüfungsgesellschaft, the German member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. Other non-US member firms are expected to join this non-exclusive alliance over the next several months.
2 KPMG Law in Germany was established in 2007 and is an independent corporate law firm associated with KPMG AG Wirtschaftsprüfungsgesellschaft and affiliated with the KPMG International Cooperative. This non-exclusive alliance with Ogletree Deakins does not include the KPMG US member firm or entities that it owns, or controls, which do not provide legal services. For cases where KPMG in the US clients require immigration and/or employment and labor law services, Ogletree Deakins may contract with these clients separately.
3 For cases where KPMG US clients require immigration and/or employment and labor law services, Ogletree Deakins would contract with these clients separately.
4 Certain member firms of the KPMG global organization, including KPMG in the US, do not provide legal services. For the purpose of this press release any commentary will be on general concepts only and is not in any way intended as legal advice or views on laws of any jurisdiction.
Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates and related entities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210509005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom